American National Bank & Trust’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$138K Hold
1,527
0.01% 283
2026
Q1
$122K Hold
1,527
0.01% 278
2025
Q4
$130K Hold
1,527
0.01% 281
2025
Q3
$119K Sell
1,527
-251
-14% -$19.6K 0.01% 275
2025
Q2
$139K Buy
1,778
+82
+5% +$6.12K 0.01% 284
2025
Q1
$123K Buy
1,696
+7
+0.4% +$501 0.01% 254
2024
Q4
$125K Hold
1,689
0.01% 242
2024
Q3
$111K Hold
1,689
0.01% 248
2024
Q2
$156K Hold
1,689
0.02% 228
2024
Q1
$161K Hold
1,689
0.02% 213
2023
Q4
$129K Hold
1,689
0.02% 207
2023
Q3
$117K Hold
1,689
0.02% 208
2023
Q2
$159K Hold
1,689
0.03% 173
2023
Q1
$140K Sell
1,689
-38
-2% -$2.99K 0.03% 174
2022
Q4
$129K Buy
1,727
+1,447
+517% +$112K 0.03% 169
2022
Q3
$23K Buy
280
+56
+25% +$5.39K 0.01% 300
2022
Q2
$21K Sell
224
-9
-4% -$932 0.01% 242
2022
Q1
$27K Buy
233
+116
+99% +$13K 0.01% 244
2021
Q4
$15K Buy
+117
New +$13.6K ﹤0.01% 259

Other funds holding EW

American National Bank & Trust's EW Position: Q2 2026 in Review

American National Bank & Trust held its Edwards Lifesciences (EW) position steady in Q2 2026 at 1,527 shares worth $138K. The position accounts for 0.01% of the portfolio, ranked #283.

American National Bank & Trust first reported a position in EW in Q4 2021 and has held it in 19 quarters since. The position peaked at $161K in Q1 2024. 372 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • American National Bank & Trust held 1,527 shares of Edwards Lifesciences worth $138K as of Q2 2026.
  • American National Bank & Trust left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up 0.01% of American National Bank & Trust's portfolio in Q2 2026, its #283 holding.
  • American National Bank & Trust first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 19 quarters since.
  • American National Bank & Trust's Edwards Lifesciences position peaked at $161K in Q1 2024.
  • 372 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on American National Bank & Trust's 13F filing for Q2 2026, filed 22 Jul 2026.